Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Head-to-Head: which seizure drug works best for kids?

NCT ID NCT07163585

Disease control Sponsor: RESnTEC, Institute of Research Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study compared two oral seizure medications, brivaracetam and levetiracetam, as first treatments in 102 children aged 1 month to 14 years with newly diagnosed epilepsy. Researchers looked at how well each drug stopped seizures and what side effects occurred. The goal is to help doctors choose the safest and most effective option for young patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
brivaracetam and levetiracetam (anti-seizure medications)
What this could lead to
If brivaracetam works as well or better with fewer side effects, it could become a preferred first-choice treatment for children with newly diagnosed epilepsy.
What could go wrong
This is a small, completed trial with 102 children, so results may not apply to all kids. Both drugs are already approved, so the main question is which is better tolerated, not a breakthrough.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

102 people

The number who actually took part.

Started

Aug 2024

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

1 month to 14 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Children of either gender * Aged 1 month to 14 years * With a clinical diagnosis of newly diagnosed epilepsy Exclusion Criteria: * History of prior use of long-term antiseizure medications * Evidence of progressive neurological disease * Metabolic abnormalities * Structural brain malformations * Incompatible with monotherapy * Severe systemic comorbidities

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Epilepsy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Epilepsy

Contacts and locations

Locations

  • The Children's Hospital and Institute of Child Health

    Multan, Punjab Province, 66000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.